DOI: http://dx.doi.org/10.18203/2349-3933.ijam20221366

Interesting presentations of mucormycosis in post-COVID patients

Veena H. A., Manjunath Bhusanoor, Bharath R., Supriya Bhakthavatchalam, Narayanswamy Madappa

Abstract


Most documented cases of mucormycosis have been reported in patients with uncontrolled diabetes mellitus, neutropenia, or treatment with corticosteroids. Recently, with the second wave of COVID-19, the Indian subcontinent has witnessed a dramatic rise in mucormycosis infection in patients recovered from COVID-19. This association has been documented in various case reports/case series and institutional studies, and the mortality associated with this fungal infection is emerging as a cause of concern. Pulmonary mucormycosis is the second most common form after rhino-orbito-cerebral mucormycosis (ROCM), but most cases are diagnosed in autopsy specimens. Cutaneous, Gastro-intestinal and disseminated forms are relatively rare. This cases series comprises of 4 cases of mucormycosis in post-COVID patients with interesting presentations. We report two cases of combined pulmonary aspergillosis and pulmonary mucormycosis, one case of rhino-orbital-mucormycosis with lymph nodal involvement and one case of rhino-orbital mucormycosis with acute inflammatory demyelinating polyneuropathy (AIDP).


Keywords


ROCM, COVID-19, Pulmonary mucormycosis, Lymph node mucormycosis, AIDP

Full Text:

PDF

References


Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses. 2001;44(7):253e60.

Sugar AM. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. fifth ed. New York, USA: Churchill Livingstone. 2000.

Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an Update. J Fungi. 2020;6(4):265.

Chander J, Kaur M, Singla N. Mucormycosis: battle with the deadly enemy over a five-year period in India. J. Fungi. 2018;4(2):46.

Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;5:26.

International Diabetes Federation. Idf diabetes atlas, 2021. Available at: https://diabetesatlas.org/en/ resources/. Accessed on 10 May 2021.

Jeong W, Keighley C, Wolfe R. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25:26e34.

Maartens G, Wood MJ. The clinical presentation and diagnosis of invasive fungal infections. J Antimicrob Chemother. 1991;28(13e22):17e44.

Pasero D, Sanna S, Liperi C, Piredda D, Branca G, Casadio L et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis, Infection. 2021;49(5):1055-60.

Zurl C, Hoenigl M, Schulz E, Hatzl S, Gorkiewicz G, Krause R et al. Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi. 2021;7(2):88.

Chen N, Zhou M, Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13.

Ibrahim A, Kontoyiannis D. Update on mucormycosis pathogenesis. Curr Opin Infect Dis. 2013;26:508-15.

Johnson A, Ghazarian Z. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol Case Rep. 2021;32:64-7.

Fanci R, Pecile P, Di Lollo S, Dini C, Bosi A. Pulmonary mucormycosis with cervical lymph node involvement in a patient with acute myeloid leukaemia: a case report. Mycoses. 2008;51(4):354-6.

Kancharu FK, Viswam V, Sreeram P. Mucormycosis of Neck a Rare Presentation. Indian J Otolaryngol Head Neck Surg. 2020;1:37-41.

Finsterer J, Scorza FA. Guillain-Barre syndrome in 220 patients with COVID-19. Egypt J Neurol Psychiatry Neurosurg. 2021;57-55.